Clinical Trials Logo

Clinical Trial Summary

Patient's with planned cesarean sections will be randomized to receive either standard 20 mU in 1L as a bolus following delivery of the placenta or 20 mu in 1L following delivery of the placenta plus an additional 20 mU in 1L over 8 hours.


Clinical Trial Description

The purpose of this study is to examine the impact of differential dose protocols commonly utilized in the post cesarean period to determine if laboratory definitions of anemia are different. Oxytocin is an antidiuretic hormone that is utilized after delivery of the fetus and placenta to contract the uterus and decrease blood loss both at the time of surgery and in the post-partum period. Here at the Penn State Hershey Medical center the investigators will use 20 units of oxytocin in a 1 L bag of LR in bolus fashion after delivery of the placenta. Other protocols use an extended course of therapy using 20 units of oxytocin in a 1 L bag of LR in a bolus plus an additional 20 units of oxytocin in a 1 L bag of LR over an 8 hour period of time.

We hypothesize that:

- Women who receive the standard 20 mU of oxytocin in 1L of LR in bolus fashion plus 20 mU in 1L over 8 hours will have a decreased reduction in pre-operative vs post-operative hematocrit and hemoglobin versus those that receive 20 mU in 1L of LR.

- Women who receive the standard 20 mU of oxytocin in 1L of LR in bolus fashion plus 20 mU in 1L over 8 hours will have decreased blood loss by weight in the postpartum period compared to patients who receive 20 mU in 1L of LR. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03361124
Study type Interventional
Source Milton S. Hershey Medical Center
Contact
Status Withdrawn
Phase Phase 4
Start date March 1, 2019
Completion date March 1, 2020

See also
  Status Clinical Trial Phase
Recruiting NCT06219538 - DAISY Uterine Drain Device Evaluation N/A
Completed NCT03959436 - Database Evaluating Outcomes of Using Carbetocin as the Primary Uterotonic Following Cesarean Delivery
Completed NCT03867383 - Calcium Chloride for Prevention of Uterine Atony During Cesarean Phase 1/Phase 2
Completed NCT03904446 - Multimodal Uterotonics at the Time of Cesarean Section in Laboring Patients Phase 4
Completed NCT06353074 - Uterine Preservation With Acar's Atony Suture for Postpartum Uterine Hemorrhage
Completed NCT05027048 - Calcium Chloride for Prevention of Blood Loss During Intrapartum Cesarean Delivery Phase 3
Recruiting NCT04833556 - Perioperative Outcomes of Postpartum Hemorrhage in Patients Undergoing Cesarean Delivery
Recruiting NCT03930407 - Serum Antimullerian Hormone Levels in Patients Who Underwent Hayman Suture